Liminatus Pharma, Inc. Class A Common Stock (LIMN) vs Lunai Bioworks Inc. (LNAI)

A side-by-side comparison of Liminatus Pharma, Inc. Class A Common Stock and Lunai Bioworks Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Liminatus Pharma, Inc. Class A Common Stock logo
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$5M
$3.85HealthcareDelayed quote: Oct 6, 2026, 12:09 PM EDT
Lunai Bioworks Inc. logo
LNAI
Lunai Bioworks Inc.
$5M
$1.15HealthcareDelayed quote: Oct 6, 2026, 12:12 PM EDT

Total return — LIMN vs LNAI

growth of $100 · dividends reinvested · last 1y
LIMN -97.3% (-97.3%/yr)LNAI -93.8% (-93.8%/yr)LNAI compounded faster over this window
020406080100Start $1002026$3$6
LIMN LNAI

LIMN vs LNAI: by the numbers

  • •LNAI is the larger company ($5M vs $5M market cap).
  • •Both run net losses; LIMN's is the smaller (0.00% vs -612568.11% net margin).

Metrics side by side

Valuation

MetricLIMNLNAI
P/S ratioN/A248.97
P/B ratio17.20N/A

Profitability

MetricLIMNLNAI
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%-612568.11%
ROE-4165.92%N/A
ROIC-225.12%N/A

Go deeper

Full LIMN analysisFull LNAI analysisInteractive comparison tool

Dig into the metrics

Liminatus Pharma, Inc. Class A Common Stock ROELunai Bioworks ROELiminatus Pharma, Inc. Class A Common Stock operating marginLunai Bioworks operating marginLiminatus Pharma, Inc. Class A Common Stock revenue growthLunai Bioworks revenue growthLiminatus Pharma, Inc. Class A Common Stock free cash flowLunai Bioworks free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.